TY - JOUR
T1 - Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors
AU - Kim, Hanseul
AU - Lipsyc-Sharf, Marla
AU - Zong, Xiaoyu
AU - Wang, Xiaoyan
AU - Hur, Jinhee
AU - Song, Mingyang
AU - Wang, Molin
AU - Smith-Warner, Stephanie A.
AU - Fuchs, Charles
AU - Ogino, Shuji
AU - Wu, Kana
AU - Chan, Andrew T.
AU - Cao, Yin
AU - Ng, Kimmie
AU - Giovannucci, Edward L.
N1 - Funding Information:
Conflicts of interest Andrew T. Chan reported receiving consulting fees from Boehringer Ingelheim, Pfizer, and Bayer Pharma. Charles Fuchs has been a consultant and/or a scientific advisor for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, and KEW. Kimmie Ng reported the following disclosures for the past 12 months: research funding from Pharmavite, Revolution Medicines, Janssen, and Evergrande Group; advisory boards for Array Biopharma, Seattle Genetics, and BiomX; and consulting for X-Biotix Therapeurics. No other disclosures were reported.
Funding Information:
Funding This work was supported by the U.S. National Institutes of Health grants [U01 CA176726, R01 CA205406, R35 CA197735, R21 CA230873, R03 CA197879, R21 CA222940, R35 CA253185, R37 CA246175, K07 CA218377, R00 CA215314], by the Department of Defense grant [CA160344], by the American Cancer Society Mentored Research Scholar Grant [MRSG-17-220-01-NEC], and by the Project P Fund. The funders of this study had no role in its design or conduct, in the collection, management, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript. Conflicts of interest Andrew T. Chan reported receiving consulting fees from Boehringer Ingelheim, Pfizer, and Bayer Pharma. Charles Fuchs has been a consultant and/or a scientific advisor for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, and KEW. Kimmie Ng reported the following disclosures for the past 12 months: research funding from Pharmavite, Revolution Medicines, Janssen, and Evergrande Group; advisory boards for Array Biopharma, Seattle Genetics, and BiomX; and consulting for X-Biotix Therapeurics. No other disclosures were reported.
Publisher Copyright:
© 2021 AGA Institute
PY - 2021/10
Y1 - 2021/10
N2 - Background & Aims: Vitamin D has been implicated in colorectal cancer (CRC) pathogenesis, but it remains unknown whether total vitamin D intake is associated with early-onset CRC and precursors diagnosed before age 50. Methods: We prospectively examined the association between total vitamin D intake and risks of early-onset CRC and precursors among women enrolled in the Nurses’ Health Study II. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for early-onset CRC were estimated with Cox proportional hazards model. Multivariable-adjusted odds ratios (ORs) and 95% CIs for early-onset conventional adenoma and serrated polyp were estimated with logistic regression model. Results: We documented 111 incident cases of early-onset CRC during 1,250,560 person-years of follow-up (1991 to 2015). Higher total vitamin D intake was significantly associated with a reduced risk of early-onset CRC (HR for ≥450 IU/day vs <300 IU/day, 0.49; 95% CI, 0.26–0.93; P for trend = .01). The HR per 400 IU/day increase was 0.46 (95% CI, 0.26–0.83). The inverse association was significant and appeared more evident for dietary sources of vitamin D (HR per 400 IU/day increase, 0.34; 95% CI, 0.15–0.79) than supplemental vitamin D (HR per 400 IU/day increase, 0.77; 95% CI, 0.37–1.62). For CRC precursors, the ORs per 400 IU/day increase were 0.76 (95% CI, 0.65–0.88) for conventional adenoma (n = 1,439) and 0.85 (95% CI, 0.75–0.97) for serrated polyp (n = 1,878). Conclusions: In a cohort of younger women, higher total vitamin D intake was associated with decreased risks of early-onset CRC and precursors.
AB - Background & Aims: Vitamin D has been implicated in colorectal cancer (CRC) pathogenesis, but it remains unknown whether total vitamin D intake is associated with early-onset CRC and precursors diagnosed before age 50. Methods: We prospectively examined the association between total vitamin D intake and risks of early-onset CRC and precursors among women enrolled in the Nurses’ Health Study II. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for early-onset CRC were estimated with Cox proportional hazards model. Multivariable-adjusted odds ratios (ORs) and 95% CIs for early-onset conventional adenoma and serrated polyp were estimated with logistic regression model. Results: We documented 111 incident cases of early-onset CRC during 1,250,560 person-years of follow-up (1991 to 2015). Higher total vitamin D intake was significantly associated with a reduced risk of early-onset CRC (HR for ≥450 IU/day vs <300 IU/day, 0.49; 95% CI, 0.26–0.93; P for trend = .01). The HR per 400 IU/day increase was 0.46 (95% CI, 0.26–0.83). The inverse association was significant and appeared more evident for dietary sources of vitamin D (HR per 400 IU/day increase, 0.34; 95% CI, 0.15–0.79) than supplemental vitamin D (HR per 400 IU/day increase, 0.77; 95% CI, 0.37–1.62). For CRC precursors, the ORs per 400 IU/day increase were 0.76 (95% CI, 0.65–0.88) for conventional adenoma (n = 1,439) and 0.85 (95% CI, 0.75–0.97) for serrated polyp (n = 1,878). Conclusions: In a cohort of younger women, higher total vitamin D intake was associated with decreased risks of early-onset CRC and precursors.
KW - Cancer Epidemiology
KW - Colorectal Adenoma
KW - Colorectal Cancer
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85112063801&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.07.002
DO - 10.1053/j.gastro.2021.07.002
M3 - Article
C2 - 34245763
AN - SCOPUS:85112063801
VL - 161
SP - 1208-1217.e9
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 4
ER -